How many Remibrutinib clinical trials are there?

18 Remibrutinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are actively recruiting participants. 3 are marked completed.

Are Remibrutinib clinical trials recruiting in 2026?

Yes — 6 Remibrutinib trials are actively recruiting in 2026, with 221 U.S. sites across 40 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Remibrutinib being studied for?

Remibrutinib is being studied for Relapsing Multiple Sclerosis, Chronic Spontaneous Urticaria, Hidradenitis Suppurativa, Chronic Spontaneous Urticaria (CSU), Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) and 11 more. The trials are grouped by indication on this page.

What phase is Remibrutinib in?

Remibrutinib clinical trials span 11 Phase 3, 4 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Remibrutinib clinical trials?

The lead sponsor across the most Remibrutinib trials is Novartis Pharmaceuticals, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.

Remibrutinib Clinical Trials (2026): 18 Studies for Relapsing Multiple Sclerosis & Chronic Spontaneous Urticaria

Creator: Hipa.ai Research
Published: 2026-05-20T23:49:14.855Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 18, 2026.

18 Remibrutinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 14 indications (including Relapsing Multiple Sclerosis & Chronic Spontaneous Urticaria) and 6,686 total planned enrollment. 11 Phase 3 Remibrutinib trials and 4 Phase 2 are listed. 7 Remibrutinib clinical trials are actively recruiting at 221 U.S. sites across 40 states. Most recent activity: NCT07225504 (Jan 2034).

Where to Participate: All Remibrutinib Trial Sites in the U.S. (221 sites across 40 states)

Every actively recruiting Remibrutinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Alabama Neurology Associates PC	Birmingham35209	NCT07225504	Map
AL	Allervie Clinical Research	Birmingham35209	NCT06868212	Map
AL	Cahaba Derm and skin hlth ctr 27	Birmingham35244	NCT06868212	Map
AZ	Research Solutions of Arizona	Litchfield Park85340	NCT06868212	Map
AZ	Peak Dermatology	Payson85541	NCT06868212	Map
AZ	Avacare Center for Dermatology	Phoenix85044	NCT06868212	Map
AZ	AZ Integrated Neuro and Spine	Phoenix85037	NCT07225504	Map
AZ	Neuromuscular Research Center	Phoenix85013	NCT06744920	Map
AZ	Premier Allergy Asthma And Immunology	Phoenix85032	NCT06868212	Map
AZ	Honor Health Research Institute	Scottsdale85258	NCT06744920	Map
AZ	Orso Health	Scottsdale85254	NCT06868212	Map
AZ	Perseverance Research Center	Scottsdale85253	NCT06846281	Map
AZ	Center for Neurosciences	Tucson85718	NCT07225504	Map
AR	Clin Trial Inst of Northwest AR	Fayetteville72703	NCT06868212	Map
AR	Acuro Research Inc	Little Rock72205	NCT06868212	Map
CA	First OC Dermatology	Fountain Valley92708	NCT06868212	Map
CA	Ctr for Dermatology Clinical Res	Fremont95438	NCT06868212	Map
CA	Fullerton Neuro and Headache Ctr	Fullerton92835	NCT06744920	Map
CA	Fullerton Neuro and Headache Ctr	Fullerton92835	NCT07225504	Map
CA	Allergy and Asthma Specialists Group	Huntington Beach92647	NCT06868212	Map
CA	University of California Irvine	Irvine92697	NCT06846281	Map
CA	Ark Clinical Research	Long Beach90815	NCT06868212	Map
CA	Orso Health	Long Beach90808	NCT06868212	Map
CA	California Allergy and Asthma Medical Group	Los Angeles90025	NCT06868212	Map
CA	Dermatology Research Associates	Los Angeles90045	NCT06868212	Map
CA	University Of Southern California	Los Angeles90033	NCT06744920	Map
CA	One Of A Kind Clinical Research	Napa94558	NCT06868212	Map
CA	Univ Cali Irvine ALS Neuromuscular	Orange92868	NCT06744920	Map
CA	Empire Clinical Research	Pomona91767	NCT06868212	Map
CA	Allergy and Asthma Consultants	Redwood City94063	NCT06868212	Map
CA	Norcal Clinical Research	Rocklin95765	NCT06868212	Map
CA	Peninsula Research Associates	Rolling Hills Estates90274	NCT06868212	Map
CA	California Pacific Medical Center	Sacramento94115	NCT06744920	Map
CA	Integrative Skin Science and Res	Sacramento95815	NCT06868212	Map
CA	UC Davis Neuromuscular Research Center	Sacramento95817	NCT06868212	Map
CA	Therapeutics Clinical Research	San Diego92123	NCT06868212	Map
CA	Dermatology Institute and Skin Care	Santa Monica90404	NCT06868212	Map
CA	Integrated Research of Inland Inc	Upland91786	NCT06868212	Map
CA	Allergy and Asthma Clin Res Inc	Walnut Creek94598	NCT06868212	Map
CA	Regina Berkovich MD PhD Inc	West Hollywood90048	NCT07225504	Map
CO	University of Colorado Hospital - Aurora	Aurora80045	NCT06868212	Map
CO	Asthma and Allergy Associates P C	Colorado Springs80907	NCT06868212	Map
CO	Colorado ENT and Allergy	Colorado Springs80909	NCT06868212	Map
CO	Skylight Health Res Inc Color Spr	Colorado Springs80917	NCT06868212	Map
CT	UCONN Health Dermatology	Farmington06030-2840	NCT06868212	Map
DC	Georgetown University Hospital	Washington D.C.20007	NCT07225504	Map
DC	Howard University Hospital Division of Geriatrics	Washington D.C.20059	NCT06868212	Map
DC	Medstar Washington Hosp Ctr	Washington D.C.20010	NCT07225504	Map
DC	Medstar Washington Hospital Center	Washington D.C.20010-2975	NCT06744920	Map
DC	Medstar Washington Hospital Center	Washington D.C.20010-2975	NCT06846281	Map
FL	Neurology of Central FL Res Ctr	Altamonte Springs32714	NCT06846281	Map
FL	Neurology of Central FL Res Ctr	Altamonte Springs32714	NCT07225504	Map
FL	Florida Ctr Allergy Asthma Research	Aventura33180	NCT06868212	Map
FL	Florida Ctr Allergy Asthma Research	Aventura33180	NCT06868212	Map
FL	SFM Clinical Research LLC	Boca Raton33487	NCT06744920	Map
FL	Skin Care Research Inc	Boca Raton33486	NCT06868212	Map
FL	Omnicure Clinical Research	Doral33172	NCT06868212	Map
FL	FXM Clinical Research Ft Laud	Fort Lauderdale33308	NCT06868212	Map
FL	UF Health Cancer Center	Gainesville32610	NCT07225504	Map
FL	University of Florida	Gainesville32610	NCT06846281	Map
FL	Skin Care Research LLC	Hollywood33021	NCT06868212	Map
FL	Homestead Assoc In Research Inc	Homestead33033	NCT06744920	Map
FL	Homestead Assoc In Research Inc	Homestead33033	NCT07225504	Map
FL	Jacksonville Center for Clinical Research	Jacksonville32216	NCT06868212	Map
FL	Neurology Associates PA	Maitland32751	NCT06744920	Map
FL	Neurology Associates PA	Maitland32751	NCT06846281	Map
FL	Neurology Associates PA	Maitland32751	NCT07225504	Map
FL	FXM Clinical Res Miami LLC	Miami33175	NCT06868212	Map
FL	Miami Dade Medical Research	Miami33176	NCT06868212	Map
FL	Miami NS Ins Baptist Health S FL	Miami33176	NCT07225504	Map
FL	University of MiamiHealth System	Miami33125	NCT06868212	Map
FL	FXM Clin Res Miramar LLC	Miramar33027	NCT06868212	Map
FL	Aqualane Clinical Research	Naples34105	NCT06846281	Map
FL	Aqualane Clinical Research	Naples34105	NCT07225504	Map
FL	Ziaderm Research LLC	North Miami Beach33162	NCT06865651	Map
FL	Ziaderm Research LLC	North Miami Beach33162	NCT06868212	Map
FL	Advent Health Orlando	Orlando32803	NCT06846281	Map
FL	AdventHealth	Orlando32804	NCT06744920	Map
FL	Comprehensive Neurology Clinic	Orlando32825	NCT07225504	Map
FL	Neurological Services of Orlando PA	Orlando32806	NCT06744920	Map
FL	Orlando Health Clinical Trials	Orlando32806	NCT06846281	Map
FL	Orlando Health Clinical Trials	Orlando32806	NCT07225504	Map
FL	Neurology Associates of Ormond Beach	Ormond Beach32174	NCT07225504	Map
FL	AllerVie Health	Panama32405	NCT06868212	Map
FL	Sarasota Clinical Research	Sarasota34233	NCT06868212	Map
FL	Lenus Research and Med Group LLC	Sweetwater33172	NCT06868212	Map
FL	Tallahassee Neurological Clinic	Tallahassee32308	NCT06846281	Map
FL	Asthma Allergy Immunology Clin Res	Tampa33613	NCT06868212	Map
FL	Axiom Brain Health	Tampa33609	NCT07225504	Map
FL	Olympian Clinical Research	Tampa33609	NCT06868212	Map
FL	University Of South Florida	Tampa33612	NCT06846281	Map
FL	Vero Beach Neurology	Vero Beach32960	NCT06846281	Map
FL	Conquest Research	Winter Park32789	NCT06868212	Map
GA	AllerVie Clin Res Columbus GA	Columbus31904	NCT06868212	Map
GA	Cleaver Medical Group	Cumming30040	NCT06868212	Map
GA	Southeast Dermatology Specialists	Douglasville30135	NCT06868212	Map
GA	Aeroallergy Research Laboratories	Savannah31406	NCT06868212	Map
GA	Joi Life Wellness Group LLC	Smyrna30080	NCT07225504	Map
HI	Hawaii Pacific Neuroscience LLC	Honolulu96817	NCT07225504	Map
ID	The Allergy Group-Meridian Clinic	Meridian83642	NCT06868212	Map
IL	Northwestern Memorial Hospital	Chicago60611	NCT07225504	Map
IL	NW Uni C and T Sciences Ins	Chicago60611	NCT06868212	Map
IL	Rush University Medical Center	Chicago60607	NCT06846281	Map
IL	University of Chicago Medical Centr	Chicago60637	NCT06744920	Map
IL	Endeavor Health	Glenview60077	NCT06865651	Map
IL	Midwest Allergy Sinus Asthma SC	Normal61761	NCT06868212	Map
IL	Clinical Res Ctr of S Illinois	O'Fallon62269	NCT06868212	Map
IL	Asthma and Allergy Center of Chicago S C	River Forest60305	NCT06868212	Map
IL	Endeavor Health Clinical Trials Center	Skokie60077	NCT06868212	Map
IL	Accellacare Duly Health and Care	Wheaton60189	NCT06868212	Map
IN	Deaconess Clin Allerg Res Inst	Evansville47715	NCT06868212	Map
IN	Southern IN Clinical Trials	New Albany47150	NCT06868212	Map
IA	McFarland Clinic PC	Ames50010	NCT06868212	Map
KS	University of Kansas Hospital	Kansas City66160	NCT06846281	Map
KS	University of Kansas Hospital	Kansas City66160	NCT07225504	Map
KY	Equity Medical LLC	Bowling Green42104	NCT06868212	Map
KY	Family Allergy And Asthma Rsch Inst	Louisville40215	NCT06868212	Map
KY	Allergy and Asthma Specialist P S C	Owensboro42301	NCT06868212	Map
LA	Ochsner Health Center	Baton Rouge70816	NCT06868212	Map
LA	Velocity Clinical Research	Lafayette70508	NCT06868212	Map
MD	Chesapeake Clinical Research Inc	Baltimore21236	NCT06868212	Map
MD	Johns Hopkins U School of Med	Baltimore21205	NCT06868212	Map
MD	Mid Atlantic Epilepsy and Sleep Ctr	Bethesda20817-1807	NCT06744920	Map
MD	Mid Atlantic Epilepsy and Sleep Ctr	Bethesda20817-1807	NCT07225504	Map
MD	Institute for Asthma and Allergy PC	Chevy Chase20815	NCT06868212	Map
MD	AllerVie Clin Res Glenn Dale	Glenn Dale20769	NCT06868212	Map
MD	MedStar Montgomery Medical Center	Olney20832	NCT06846281	Map
MA	Boston Specialists LLC	Boston02111	NCT06868212	Map
MA	Neuromuscular Diagnostic Center	Boston02114	NCT06744920	Map
MA	Tufts Medical Center	Boston02111	NCT06846281	Map
MA	Lahey Hospital and Medical Center	Burlington01805	NCT06846281	Map
MA	Neuro Institute of New England P C	Foxborough02035	NCT07225504	Map
MA	Neurology Center of New England PC	Foxborough02035	NCT06846281	Map
MI	ClinSite Inc	Ann Arbor48106-0525	NCT06868212	Map
MI	Derm Institute West Michigan PLLC	Caledonia49316	NCT06868212	Map
MI	Henry Ford Hospital	Detroit48202	NCT06868212	Map
MI	Michigan State University-Department of Neurology	East Lansing48824	NCT06744920	Map
MI	Michigan Institute of Neurological	Farmington Hills48334	NCT06846281	Map
MI	Michigan Institute of Neurological	Farmington Hills48334	NCT07225504	Map
MI	Memorial HC Ins for Neuroscience	Owosso48867	NCT06846281	Map
MI	Revival Research Institute	Troy48084	NCT06868212	Map
MI	Somerset Skin Centre	Troy48084	NCT06868212	Map
MN	Clinical Research Institute	Minneapolis55402	NCT06868212	Map
MN	University of Minnesota	Minneapolis55455	NCT06868212	Map
MN	Mayo Clinic - Rochester	Rochester55905	NCT06868212	Map
MO	ENT and Allergy Center of Missouri	Columbia65201	NCT06868212	Map
MO	The Clinical Research Center	St Louis63141	NCT06868212	Map
MO	WA Uni School Of Med	St Louis63110	NCT06846281	Map
MO	Washington University	St Louis63141	NCT06868212	Map
NE	Somnos Clinical Research	Lincoln68510	NCT06868212	Map
NV	Allergy and Asthma Center of Las Vegas	Las Vegas89128	NCT06868212	Map
NV	Cleveland Clinic Foundation	Las Vegas89106	NCT06846281	Map
NV	Las Vegas Dermatology	Las Vegas89144	NCT06868212	Map
NJ	Hudson Essex Allergy-Circuit Clinical	Belleville07109	NCT06868212	Map
NJ	Circuit Clinical Mercer Algy Pulm	Hamilton08619	NCT06868212	Map
NJ	Allergy Asthma Assoc Monmouth	Little Silver07739	NCT06868212	Map
NJ	Allergy Partners of New Jersey PC	Ocean Township07712	NCT06868212	—
NJ	Circuit Clinical	Riverdale07457	NCT06868212	Map
NJ	Holy Name Medical Center	Teaneck07666	NCT06846281	Map
NM	University of New Mexico	Albuquerque87131-0001	NCT06846281	Map
NM	University of New Mexico Hospital	Albuquerque87106	NCT07225504	Map
NY	Dent Neurological Institute	Buffalo14209	NCT06744920	Map
NY	SUNY Buffalo The Jacobs Neuro Inst	Buffalo14203	NCT06846281	Map
NY	Equity Medical	The Bronx10455	NCT06868212	Map
NY	Montefiore Medical Center	The Bronx10467	NCT06868212	Map
NC	Allergy Partners Of West NC	Asheville28801	NCT06868212	Map
NC	UNC DermatologyandSkinCancer Ctr	Chapel Hill27516	NCT06868212	Map
NC	Velocity Clinical Research	Raleigh27607	NCT06846281	Map
ND	Sanford Health	Fargo58122	NCT06846281	Map
OH	Premier Health	Centerville45459	NCT06846281	Map
OH	Bernstein Clinical Research Center	Cincinnati45231	NCT06868212	Map
OH	Univ of Cincinnati Medical Center	Cincinnati45219	NCT06744920	Map
OH	Univ of Cincinnati Medical Center	Cincinnati45219	NCT06846281	Map
OH	Cleveland Clinic Foundation	Cleveland44195	NCT06744920	Map
OH	Cleveland Clinic Foundation	Cleveland44195	NCT06846281	Map
OH	CR Services Acquisition US	Columbus43213	NCT06868212	Map
OH	Ohio Health Research Institute	Columbus43214	NCT06846281	Map
OH	Wright State University	Fairborn45324	NCT06868212	Map
OH	Toledo Institute of Clinical Research	Toledo43617	NCT06868212	Map
OK	Unity Clinical Research	Oklahoma City73118	NCT06868212	Map
OK	Vital Prospects Clinical Research Institute	Tulsa74136	NCT06868212	Map
OR	Oregon Health Sciences University	Portland97239	NCT06868212	Map
OR	Oregon Medical Research Center	Portland97223	NCT06868212	Map
PA	Allergy and Clinical Immunology Associates	Pittsburgh15241	NCT06868212	Map
PA	University of Pittsburgh Medical Center	Pittsburgh15213	NCT06744920	Map
SC	Medical Univ Of SC Medical Ctr	Charleston29425	NCT06868212	Map
SC	Allergic Disease and Asthma Center	Greenville29607	NCT06868212	Map
SC	Premier Neurology	Greenville29605	NCT06846281	Map
SC	Premier Neurology	Greenville29605	NCT07225504	Map
SC	Tribe Clinical Research LLC	Greenville29601	NCT06868212	Map
SC	Charleston ENT and Allergy	North Charleston29406	NCT06868212	Map
SC	National Allergy and Asthma Research LLS	North Charleston29420	NCT06868212	Map
TN	Neurology Clinic PC	Cordova38018	NCT07225504	Map
TN	Sibyl Wray MD Neurology PC	Knoxville37922	NCT06846281	Map
TN	International Clinical Research Tennessee LCC	Murfreesboro37130	NCT06868212	Map
TX	Arlington Center for Dermatology	Arlington76011	NCT06868212	Map
TX	Austin Regional Clinic	Austin78731	NCT06846281	Map
TX	Orion Clinical Research	Austin78759	NCT06868212	Map
TX	Bellaire Dermatology Associates	Bellaire77401	NCT06868212	Map
TX	Pharma Research and Amp Consult	Dallas75231	NCT06868212	Map
TX	Reveal Research Institute	Dallas75230	NCT06868212	Map
TX	Univ of Texas Southwest Med Center	Dallas75390-9034	NCT06846281	Map
TX	Western Sky Medical Research	El Paso79924	NCT06868212	Map
TX	John Peter Smith Hospital	Fort Worth76104	NCT06846281	Map
TX	Center for Clinical Studies	Houston77030	NCT06868212	Map
TX	Houston Methodist Hospital	Houston77030	NCT06744920	Map
TX	UT Health Science Center	Houston77030	NCT06744920	Map
TX	Sante Clinical Research	Kerrville78028	NCT06868212	Map
TX	Saturn Research Solution	Plano75024	NCT07225504	Map
TX	Saturn Research Solutions LLC	Plano75024	NCT06846281	Map
TX	Andante Research	San Antonio78229	NCT06868212	Map
TX	RFSA Dermatology	San Antonio78213	NCT06868212	Map
UT	University Of Utah	Murray84107	NCT06868212	Map
UT	Allergy Associates of Utah	Sandy City84093	NCT06868212	Map
VA	Forefront Dermatology	Vienna22182	NCT06868212	Map
WA	Bellingham Asthma Allergy and Immunology	Bellingham98225	NCT06868212	Map
WA	University of WA Division of Cardio	Seattle98195	NCT06744920	Map
WA	University of Washington MS Clinic	Seattle98133	NCT07225504	Map
WA	Citta Clinical Research	Spokane99202	NCT07225504	Map
WI	Center for Neurological Disorders G	Greenfield53228-1321	NCT06744920	Map
WI	Center for Neurological Disorders G	Greenfield53228-1321	NCT06846281	Map

Remibrutinib clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	terminated	not yet recruiting	available	Total
P1			2				2
P2	1		1	1	1		4
P3	5	6					11
N/A						1	1

Recruiting Remibrutinib clinical trials (7)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT07225504	REMASTERA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis	P3	Secondary Progressive Multiple Sclerosis (SPMS)	1,275	Nov 2025
NCT06744920	RELIEVEA Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis	P3	Generalized Myasthenia Gravis	180	Feb 2025
NCT07456891	Remibrutinib Open Label Roll-over Post-trial Access Protocol	P3	Indication of the Parent Protocol	212	Apr 2026
NCT06846281	Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.	P3	Relapsing Multiple Sclerosis	360	Jul 2025
NCT07222956	RemiSevenA Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS	P2	Multiple Sclerosis (MS) - Relapsing-remitting	20	Jun 2026
NCT06865651	LOU064Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria	P2	Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)	44	May 2025
NCT06868212	RECLAIMA Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines	P3	Chronic Spontaneous Urticaria (CSU)	400	Jul 2025

Remibrutinib clinical trials by indication

Relapsing Multiple Sclerosis (3)

NCT	Acronym	Phase	Status	Title
NCT06846281	—	P3	recruiting	Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT05147220	REMODEL-1	P3	active not recruiting	Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281	REMODEL-2	P3	active not recruiting	Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Hidradenitis Suppurativa (2)

NCT	Acronym	Phase	Status	Title
NCT06840392	RECHARGE-2	P3	active not recruiting	A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06799000	RECHARGE 1	P3	active not recruiting	A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

Chronic Spontaneous Urticaria (2)

NCT	Acronym	Phase	Status	Title
NCT06042478	—	P3	active not recruiting	Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT05170724	—	N/A	available	Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria

Indication of the Parent Protocol (1)

NCT	Acronym	Phase	Status	Title
NCT07456891	—	P3	recruiting	Remibrutinib Open Label Roll-over Post-trial Access Protocol

Multiple Sclerosis (MS) - Relapsing-remitting (1)

NCT	Acronym	Phase	Status	Title
NCT07222956	RemiSeven	P2	not yet recruiting	A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

Secondary Progressive Multiple Sclerosis (SPMS) (1)

NCT	Acronym	Phase	Status	Title
NCT07225504	REMASTER	P3	recruiting	A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Autoimmune and Chronic Inflammatory Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT07032272	—	P1	completed	A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

Chronic Spontaneous Urticaria (CSU) (1)

NCT	Acronym	Phase	Status	Title
NCT06868212	RECLAIM	P3	recruiting	A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) (1)

NCT	Acronym	Phase	Status	Title
NCT06865651	LOU064	P2	recruiting	Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

Generalized Myasthenia Gravis (1)

NCT	Acronym	Phase	Status	Title
NCT06744920	RELIEVE	P3	recruiting	A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Chronic Inducible Urticaria (1)

NCT	Acronym	Phase	Status	Title
NCT05976243	—	P3	active not recruiting	A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Hepatic Impairment (1)

NCT	Acronym	Phase	Status	Title
NCT05753592	—	P1	completed	A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants

Allergy, Peanut (1)

NCT	Acronym	Phase	Status	Title
NCT05432388	—	P2	completed	Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Sjögren Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT04035668	LOUiSSe	P2	terminated	A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

Remibrutinib pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
REMASTER	NCT07225504	P3	recruiting	Secondary Progressive Multiple Sclerosis (SPMS)	1,275	—
RELIEVE	NCT06744920	P3	recruiting	Generalized Myasthenia Gravis	180	—
REMODEL-1	NCT05147220	P3	active not recruiting	Relapsing Multiple Sclerosis	1,000	—
REMODEL-2	NCT05156281	P3	active not recruiting	Relapsing Multiple Sclerosis	1,007	—
RECHARGE-2	NCT06840392	P3	active not recruiting	Hidradenitis Suppurativa	565	—
RECHARGE 1	NCT06799000	P3	active not recruiting	Hidradenitis Suppurativa	588	—
RECLAIM	NCT06868212	P3	recruiting	Chronic Spontaneous Urticaria (CSU)	400	PMID 41854973
RemiSeven	NCT07222956	P2	not yet recruiting	Multiple Sclerosis (MS) - Relapsing-remitting	20	—
LOU064	NCT06865651	P2	recruiting	Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)	44	—
LOUiSSe	NCT04035668	P2	terminated	Sjögren Syndrome	73	PMID 37932009

Terminated and withdrawn Remibrutinib trials (1)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT04035668terminatedA Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

All Remibrutinib trials (18)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT07225504	REMASTER	A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis	P3	recruiting	1,275	Novartis Pharmaceuticals	Nov 2025
NCT06744920	RELIEVE	A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis	P3	recruiting	180	Novartis Pharmaceuticals	Feb 2025
NCT07456891		Remibrutinib Open Label Roll-over Post-trial Access Protocol	P3	recruiting	212	Novartis Pharmaceuticals	Apr 2026
NCT06846281		Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.	P3	recruiting	360	Novartis Pharmaceuticals	Jul 2025
NCT07222956	RemiSeven	A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS	P2	not yet recruiting	20	Moein Amin	Jun 2026
NCT05147220	REMODEL-1	Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)	P3	active not recruiting	1,000	Novartis Pharmaceuticals	Dec 2021
NCT05156281	REMODEL-2	Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)	P3	active not recruiting	1,007	Novartis Pharmaceuticals	Dec 2021
NCT05976243		A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines	P3	active not recruiting	362	Novartis Pharmaceuticals	Dec 2023
NCT06840392	RECHARGE-2	A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa	P3	active not recruiting	565	Novartis Pharmaceuticals	Mar 2025
NCT06799000	RECHARGE 1	A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)	P3	active not recruiting	588	Novartis Pharmaceuticals	Jan 2025
NCT06865651	LOU064	Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria	P2	recruiting	44	Novartis Pharmaceuticals	May 2025
NCT06042478		Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.	P3	active not recruiting	470	Novartis Pharmaceuticals	Nov 2023
NCT06868212	RECLAIM	A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines	P3	recruiting	400	Novartis Pharmaceuticals	Jul 2025
NCT07032272		A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.	P1	completed	16	Novartis Pharmaceuticals	Jul 2025
NCT05432388		Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts	P2	completed	76	Novartis Pharmaceuticals	Oct 2022
NCT05753592		A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants	P1	completed	38	Novartis Pharmaceuticals	Oct 2022
NCT05170724		Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria	—	available	0	Novartis Pharmaceuticals	—
NCT04035668	LOUiSSe	A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome	P2	terminated	73	Novartis Pharmaceuticals	Jul 2019

Remibrutinib clinical trials: frequently asked questions

How many Remibrutinib clinical trials are there?: 18 Remibrutinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are actively recruiting participants. 3 are marked completed.
Are Remibrutinib clinical trials recruiting in 2026?: Yes — 6 Remibrutinib trials are actively recruiting in 2026, with 221 U.S. sites across 40 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Remibrutinib being studied for?: Remibrutinib is being studied for Relapsing Multiple Sclerosis, Chronic Spontaneous Urticaria, Hidradenitis Suppurativa, Chronic Spontaneous Urticaria (CSU), Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) and 11 more. The trials are grouped by indication on this page.
What phase is Remibrutinib in?: Remibrutinib clinical trials span 11 Phase 3, 4 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Remibrutinib clinical trials?: The lead sponsor across the most Remibrutinib trials is Novartis Pharmaceuticals, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Remibrutinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 18, 2026.

Related pages on Hipa.ai:

Remibrutinib overview Remibrutinib evidence & publications